U.S. markets closed

Rocket Pharmaceuticals, Inc. (RCKT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
43.19-0.68 (-1.55%)
At close: 4:00PM EDT

43.19 0.00 (0.00%)
After hours: 4:31PM EDT

Rocket Pharmaceuticals, Inc.

9 Cedarbrook Drive
Suite 7530 350 Fifth Avenue
Cranbury, NJ 08512
United States
646 440 9100
http://www.rocketpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees91

Key Executives

NameTitlePayExercisedYear Born
Dr. Gaurav ShahCEO & Director840.34kN/A1975
Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBAPres, COO & Head of Devel.683.91kN/A1979
Mr. Carlos Garcia-Parada M.B.A.Chief Financial OfficerN/AN/A1965
Mr. John C. MilitelloVP of Fin., Sr. Controller, Treasurer & Principal Accounting OfficerN/AN/A1973
Dr. Claudine Prowse Ph.D.Sr. VP of Strategy and Head of Investor Relations & Corp. Devel.N/AN/AN/A
Ms. Sara TurkenSr. Director of Legal & Compliance and Corp. Sec.N/AN/AN/A
Mr. Jonathan SchwartzChief Medical Officer & Sr. VP of Clinical Devel.N/AN/A1964
Dr. Gayatri R. Rao J.D., M.D.Global Program Head of FA, LAD-I & PKD Programs and VPN/AN/AN/A
Mr. Raj PrabhakarSr. VP & Chief Bus. OfficerN/AN/AN/A
Mr. Jose Trevejo M.D., Ph.D.Chief Devel. Officer of AAV & Sr. VPN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Corporate Governance

Rocket Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.